Drug Cardiovascular

Eliquis

Payments companies reported to CMS as associated with Eliquis. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$7.9Massociated payments (2023-2025)

84,400clinicians with associated payments

8companies reporting

By year

2023 $3.1M

2024 $2.5M

2025 $2.3M

Payments reported as associated with Eliquis, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Internal Medicine $1.6M

Cardiovascular Disease $1.4M

Family Medicine $1.1M

Family $803K

Interventional Cardiology $457K

Physician Assistant $429K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Eliquis

These are the largest totals companies reported as associated with Eliquis. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Steven Deitelzweig	New Orleans, LA	Internal Medicine	$197,457.70
Daniel Singer	Boston, MA	Internal Medicine	$78,068.25
Elliott Antman	Boston, MA	Cardiovascular Disease	$45,000.00
Jonathan Handler	Northbrook, IL	Emergency Medicine	$40,643.85
Charles Kinder	Berwyn, IL	Clinical Cardiac Electrophysiology	$37,992.99
Brett Atwater	Fairfax, VA	Clinical Cardiac Electrophysiology	$22,600.00
Jonathan Hsu	San Diego, CA	Clinical Cardiac Electrophysiology	$21,250.00
Luis Rosado Carrillo	Guaynabo, PR	Cardiovascular Disease	$20,917.40
Ramon Perea	San Juan, PR	Cardiovascular Disease	$20,846.78
Sarabjeet Singh	Bakersfield, CA	Cardiovascular Disease	$18,788.46

Prescribed Eliquis?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.